NCT02352844View on ClinicalTrials.gov

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 7, 2015

Primary Completion Date

August 15, 2017

Study Completion Date

August 15, 2017

Conditions
Solid MalignancySolid Tumor
Interventions
DRUG

Everolimus

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT02352844 - Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations | Biotech Hunter | Biotech Hunter